Cox-2 Inhibitors – in the news again

The information is coming in so fast that it’s hard to keep up to date! Many of you read in the last issue of HeadWay about emerging concerns about drugs such as Celebrex and Bextra. Now these drugs are getting more attention, and more studies are being done. You will notice some updates in this article about Cox2 Inhibitors, which will hopefully clear up some of your questions. Although the Vice-President of the US National Cancer Institute urges caution about jumping to conclusions about this study, I think we should continue to be cautious about using these drugs until more studies are completed.